Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma

ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic...

ARQL : 1.50 (-0.66%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 3.08 (+1.65%)
ARQL : 1.50 (-0.66%)
RGBP : 0.0659 (-11.54%)
RGBPP : 0.0560 (unch)
ECYT : 4.97 (+0.61%)
CASI : 3.52 (+1.73%)
ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2017 / ArQule, Inc. (NASDAQ: ARQL) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 9:00 AM Eastern Time.

ARQL : 1.50 (-0.66%)
ArQule Reports Third Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017.

ARQL : 1.50 (-0.66%)
ArQule Announces $9.5 Million Private Placement of Preferred Stock

--Ran Nussbaum, Managing Partner and co-founder of The Pontifax Group, joins ArQule Board

ARQL : 1.50 (-0.66%)
FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to miransertib (ARQ 092) for the treatment of Proteus...

ARQL : 1.50 (-0.66%)
ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017. The Company will hold...

ARQL : 1.50 (-0.66%)
ArQule Announces $15.7 Million Private Placement of Common Stock

ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.P., pursuant to which the...

ARQL : 1.50 (-0.66%)
ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of Research and Development and Chief Medical Officer, will present...

ARQL : 1.50 (-0.66%)
ArQule Reports Second Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017.

ARQL : 1.50 (-0.66%)
ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malignancies refractory to...

ARQL : 1.50 (-0.66%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

ARQL : 1.50 (-0.66%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK , June 26, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach...

ARQL : 1.50 (-0.66%)
ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress in Madrid,...

ARQL : 1.50 (-0.66%)
ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with Overgrowth Diseases...

ARQL : 1.50 (-0.66%)
ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that data from a phase 1/2 trial with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, presented at ASCO demonstrate a meaningful clinical...

ARQL : 1.50 (-0.66%)
ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models will be presented on June 23, 2017...

ARQL : 1.50 (-0.66%)
Investor Network: ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 3, 2017 / ArQule, Inc. (NASDAQ: ARQL) will be discussing their earnings results in their Q1 Earnings Call to be held May 3, 2017 at 9:00 AM Eastern Time.

ARQL : 1.50 (-0.66%)
ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, will present...

ARQL : 1.50 (-0.66%)
Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma

ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving...

ARQL : 1.50 (-0.66%)

Van Meerten Stock Picks

5 Great Large Caps
Today I wanted to find 5 Large Caps that still had some upside potential.
ALL +0.05 , AMP +0.31 , LB +0.03 , AXP +0.41 , AKAM +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.09%) this morning are up +0.08% and European stocks are down -0.12% . Most global stocks markets moved higher ahead of central bank meetings this week from the Fed, ECB and BOE. U.S.... Read More

Chart of the Day

Chart of the Day

Viking Therapeutics (VKTX) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter, a Weighted Alpha of 206.52+ and gained 254.95% in the last year
Read More

Brugler Ag Report

Today's Commentary

Corn futures are 1 to 2 cents lower this morning, with speculative attention drawn toward the beginning of bitcoin futures trading (+26% at one point overnight!). They saw gains of 1/4 to 1 1/4 cents on Friday, but nearby Dec was 1.38% for the week. ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.